NASDAQ:ARIA Ariad Pharmaceuticals - ARIA Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ariad Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Add Share Share Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$4.67▼$23.99VolumeN/AAverage Volume15.70 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media About Ariad Pharmaceuticals (NASDAQ:ARIA) StockARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).Read More Receive ARIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ariad Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARIA Stock News HeadlinesMarch 29, 2023 | marketwatch.comBile Duct Cancer Drug Market Growing Demand and Trends 2023 to 2031March 27, 2023 | marketwatch.comAnti-Cancer Drug Market Size and Forecast till 2031March 31, 2023 | Porter & Company (Ad)Biden's corruption knows no endPorter Stansberry here -- I reveal the shocking changes this Obama policy will usher in… what it means for you, your family, and your finances… and how you can prepare for this new American era. Stream my new documentary at no cost today.March 26, 2023 | marketwatch.comGlobal Cancer Drugs Market 2023 Projection, Growth Rate and Emerging Trends Analysis to 2030 By VMReportsMarch 22, 2023 | marketwatch.comIclusig Market Top Players and Forecast till 2031March 14, 2023 | marketwatch.comPonatinib Market Size 2023 to 2028 By Deployment, Growth Factor and Production costMarch 11, 2023 | marketwatch.comThe Evolution of Bile Duct Cancer Drug Market 2023: Future Developments and Trends by 2028March 10, 2023 | marketwatch.com2023-2029 Anti-Cancer Drug Market Size and Latest Trends Analysis | Research Report by Absolute ReportsMarch 31, 2023 | Porter & Company (Ad)Biden's corruption knows no endPorter Stansberry here -- I reveal the shocking changes this Obama policy will usher in… what it means for you, your family, and your finances… and how you can prepare for this new American era. Stream my new documentary at no cost today.March 8, 2023 | marketwatch.comGrowth Analysis on Proto-Oncogene Drgu Market Size 2023-2028 with Prominent Manufacturers | Research Report by Absolute ReportsMarch 7, 2023 | marketwatch.comForecasting the Future of Chronic Myeloid Leukemia (CML) Treatment Market: Analysing Emerging Trends and Opportunities 2023-2028March 4, 2023 | marketwatch.comGlobal Targeted Drug EGFR RTK Inhibitors for NSCLC Market Opportunities, Business Statistics Research Report 2030 By VMReportsMarch 4, 2023 | marketwatch.comGlobal Targeted Drugs for NSCLC Market Size Analysis, Share, Application, Opportunities Forecast to 2030 By VMReportsMarch 4, 2023 | marketwatch.comGlobal Anti-Cancer Drug Market 2023 Industry Share, Analysis of Competitive Landscape and Forecast 2030 By VMReportsMarch 1, 2023 | marketwatch.comGlobal Acute Lymphocytic / Lymphoblastic Leukemia Drugs Market Upcoming Trends, Opportunities by Types and Application to 2030 By VMReportsMarch 1, 2023 | marketwatch.comIn Depth Research on Uterine Cancer Therapies and Diagnostic Market Report 2023-2029February 27, 2023 | marketwatch.comGlobal Proto-Oncogene Drgu Market Size 2023 Business Strategies, Growth Analysis, Regional Demand, 2030 Forecast Research Report By VMReportsFebruary 27, 2023 | marketwatch.comBile Duct Cancer Drug Market 2023 Size, Share, Growth, Analysis, Trends and Forecast to 2028February 22, 2023 | marketwatch.comChronic Myeloid Leukemia (CML) Treatment Market is Booming by Size, Revenue, Trend and Top Growing Companies 2023-2028February 22, 2023 | marketwatch.comPonatinib Market Growth, Business Overview and Forecast to 2028February 20, 2023 | marketwatch.comPersonalizing Cancer Drugs Market Booming With Rising Demands and Massive Opportunities, 2023 - 2029February 19, 2023 | marketwatch.comGlobal Acute Lymphoblastic Leukemia Market Competitive Intelligence, Demand Generation Strategies, and Business Forecast 2023 – 2030 By VMReportsFebruary 19, 2023 | marketwatch.comGlobal Personalizing Cancer Drugs Market Future Growth, Regional Analysis, Leading Players Updates, Industry Demand by Forecast to 2030 By VMReportsFebruary 17, 2023 | thestreet.comActivist Hedge Fund Seeks Firing of Ariad Pharma CEO BergerFebruary 16, 2023 | marketwatch.comCancer Drugs Market 2023 : Global Industry Share, Key Dynamics and Forecast to 2028February 16, 2023 | marketwatch.comAnti-Cancer Drug Market Size, Share, Report Analysis & Forecast [2023-2028] with Top Countries DataFebruary 11, 2023 | marketwatch.comFuture of Bile Duct Cancer Drug Market with Comprehensive Study and Industry Trends 2023-2028See More Headlines Receive ARIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ariad Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARIA Company Calendar Last Earnings7/28/2016Today3/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:ARIA CUSIP04033A10 CIK884731 Webwww.ariad.com Phone+1-617-4940400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A ARIA Stock - Frequently Asked Questions How were Ariad Pharmaceuticals' earnings last quarter? Ariad Pharmaceuticals Inc (NASDAQ:ARIA) released its quarterly earnings data on Thursday, July, 28th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.70. The pharmaceutical company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $60.64 million. Ariad Pharmaceuticals's revenue for the quarter was up 133.0% compared to the same quarter last year. During the same period last year, the company earned ($0.28) earnings per share. What other stocks do shareholders of Ariad Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ariad Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Twitter (TWTR), Exelixis (EXEL), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Achillion Pharmaceuticals (ACHN), Array Technologies (ARRY), Alphabet (GOOG), Netflix (NFLX) and Ford Motor (F). What is Ariad Pharmaceuticals' stock symbol? Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA." What is Ariad Pharmaceuticals' stock price today? One share of ARIA stock can currently be purchased for approximately $23.99. How can I contact Ariad Pharmaceuticals? Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The official website for the company is www.ariad.com. The pharmaceutical company can be reached via phone at +1-617-4940400. This page (NASDAQ:ARIA) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.